Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UHUMZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IBI-354
|
|||||
| Synonyms |
IBI 354; IBI-354; IBI354
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics (Suzhou) Co. Ltd.
|
|||||
| Drug Status |
Phase 3
|
|||||
| Indication |
In total 4 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
PODS-CHX-A"-DTPA
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
